Chart 1. Essential characteristics of the included studies.
| Author, year | Country | Intervention group | Comparator group | Number of patients in the intervention group | Number of patients in the comparator group | Percentage of women in the intervention group | Percentage of women in the comparator group | Age of patients in the intervention group (years), mean (SD) | Age of patients in the comparator group (years), mean (SD) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIRA 25mg | MIRA 50mg | MIRA 25mg | MIRA 50mg | MIRA 25mg | MIRA 50mg | |||||||
| Chapple et al. (2013) 8 | Multicentric | MIRA 25 e 50mg | TOL ER 4mg | 167 | 167 | 85 | 88% | 89.2% | 81.2% | 57,2 (12,1) | 56,9 (12,5) | 56,6 (12,8) |
| Chapple et al. (2013) 9 | Multicentric | MIRA 50mg | TOL ER 4mg | NA | 812 | 812 | NA | 74.1% | 73.9% | NA | 59.2 (12.6) | 59.6 (12.5) |
| Khullar et al. (2013) 10 | Multicentric | MIRA 50mg | TOL ER 4mg | NA | 493 | 495 | NA | 72.4% | 72.9% | NA | 59.1 (12.3) | 59.1 (12.9) |
| Yamaguchi et al. (2014) 11 | Multicentric | MIRA 50mg | TOL ER 4mg | NA | 369 | 368 | NA | 84.3% | 82.6% | NA | 58.3 (13.9) | 58.3 (13.7) |
| Abrams et al. (2015) 12 | Multicentric | MIRA 25 e 50mg | SOL 2.5mg, 5mg e 10mg | 77 | 78 | 313 | 67.5% | 66.67% | 66.1% | 55.2 (14.5) | 53.4 (14.0) | 54,88 (13,9) |
| Batista et al. (2015) 13 | Multicentric | MIRA 50mg | SOL 5mg | NA | 936 | 934 | NA | 76.1% | 75.9% | NA | 56.7 (14.3) | 57.4 (13.6) |
| Kuo et al. (2015) 14 | Multicentric | MIRA 50mg | TOL ER 4mg | NA | 338 | 333 | NA | 67.5% | 64% | NA | 54.3 (14.2) | 53.9 (14.5) |
| Kuo et al. (2015) 15 | Multicentric | MIRA 50mg | TOL ER 4mg | NA | 76 | 74 | NA | 61.8% | 59.5% | NA | 59.0 (15.1) | 56.4 (15.8) |
| Vecchioli Scaldazza and Morosetti (2016) 16 | Italy | MIRA 50mg | SOL 5mg | NA | 31 | 29 | NA | 100% | 100% | NA | 56 (6.25) | 58 (7.0) |
| Herschorn et al. (2017) 17 | Multicentric | MIRA 25 e 50mg | SOL 5mg | 423 | 422 | 423 | 77.3% | 76.5% | 78.3% | 56.9 (13.6) | 56.7 (13.3) | 58.2 (12.8) |
| Hsiao et al. (2018) 18 | Multicentric | MIRA 50mg | TOL ER 4mg | NA | 12 | 12 | NA | 100% | 100% | NA | 53 (3.5) | 48,75 (2.6) |
| Gratzke et al. (2018) 19 | Multicentric | MIRA 50mg | SOL 5mg | NA | 302 | 299 | NA | 79% | 81% | NA | 61 (10.7) | 60 (11.2) |
| Staskin et al. (2018) 20 | Multicentric | MIRA 25mg | TOL ER 4mg | 316 | NA | 310 | 73.4% | NA | 75.2% | 53.4 (13.9) | NA | 53.2 (13.7) |
| White et al. (2018) 21 | Multicentric | MIRA 25 e 50mg | SOL 5mg | 423 | 422 | 423 | 77,3% | 76,5% | 78,3% | 56,9 | 56,7 | 58,2 |
Abbreviations: MIRA, Mirabegron; NA, Not available; SOL, Solifenacin; SD, Standard deviation; TOL, Tolterodine.